Template:HIV post-exposure prophylaxis regimens: Difference between revisions
No edit summary |
(/* Preferred HIV PEP RegimenKuhar D, et al. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. September 2013. 34(9):875-892. DOI: 1...) |
||
| Line 1: | Line 1: | ||
===Preferred HIV [[PEP]] Regimen<ref>Kuhar D, et al. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. September 2013. 34(9):875-892. DOI: 10.1086/672271. http://www.jstor.org/stable/10.1086/672271</ref><ref>Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services</ref>=== | ===Preferred HIV [[PEP]] Regimen<ref>Kuhar D, et al. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. September 2013. 34(9):875-892. DOI: 10.1086/672271. http://www.jstor.org/stable/10.1086/672271</ref><ref>Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services</ref>=== | ||
''CDC preferred regimen for '''28 days''' '' | |||
*[[Raltegravir]] (Isentress; RAL) 400 mg PO twice daily, '''plus''' | *[[Raltegravir]] (Isentress; RAL) 400 mg PO twice daily, '''plus''' | ||
*[[Truvada]], 1 PO once daily (Tenofovir DF [Viread; TDF] 300 mg emtricitabine [Emtriva; FTC] 200 mg) | *[[Truvada]], 1 PO once daily (Tenofovir DF [Viread; TDF] 300 mg emtricitabine [Emtriva; FTC] 200 mg) | ||
*If known source patient with resistant HIV strain, consult HIV service for source-patient-specific PEP | |||
^Consider interactions with current medication interactions and contraindications, such as renal impairment with Truvada | |||
Revision as of 19:03, 19 November 2017
Preferred HIV PEP Regimen[1][2]
CDC preferred regimen for 28 days
- Raltegravir (Isentress; RAL) 400 mg PO twice daily, plus
- Truvada, 1 PO once daily (Tenofovir DF [Viread; TDF] 300 mg emtricitabine [Emtriva; FTC] 200 mg)
- If known source patient with resistant HIV strain, consult HIV service for source-patient-specific PEP
^Consider interactions with current medication interactions and contraindications, such as renal impairment with Truvada
- ↑ Kuhar D, et al. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. September 2013. 34(9):875-892. DOI: 10.1086/672271. http://www.jstor.org/stable/10.1086/672271
- ↑ Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services